首页 / 院系成果 / 成果详情页

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial 期刊论文

编号：

A65F3748CF741E447D00FF9CFBBE6CDC
作者：

Tang, Tiantian#^[1]Wang, Jingxuan#^[2]Sun, Tao#^[3]Zhang, Lina^[1];Li, Fanfan^[4];Zhao, Bing^[5];Han, Guohui^[6];Tong, Zhongsheng(佟仲生)^[7]Yang, Hua^[8];Yin, Yongmei^[9];Kong, Xiangshun^[10];Wang, Ying^[11];Nie, Jianyun^[12];Ma, Lixia^[13];Zhang, Yongqiang^[14];Luo, Jing^[15];Shan, Changping^[16];Yao, Jing^[17];Tan, Shisheng^[18];Ling, Xiaoling^[19];Sun, Hongmei^[20];Li, Huihui^[21];Ma, Li^[1];Zhou, Tao^[1];Liu, Yunjiang^[1];Qi, Yixin^[1];Song, Zhenchuan^[1];Li, Yuntao^[1];Yang, Chao^[1];Hui, Tianli^[1];Wang, Meiqi^[1];Wang, Haoqi^[1];Zhang, Xi^[1];Zhao, Wenhui^[2];Li, Yanhui^[22];Li, Mengmeng^[22];Xin, Ying^[22];Luo, Xuan^[22];Yi, Deliang^[22];Luo, Hongmei^[22];Liu, Huan^[22];Lu, Qianyun^[22];Yuan, Jing^[22];Geng, Cuizhi*^[1]Zhang, Qingyuan(张清媛)*^[2]
语种：

英文
期刊：

BIOMOLECULES AND BIOMEDICINE ISSN：2831-0896 2026 年 ; 2026 JUL 21
收录：
关键词：

SYHX2011 updated analysis phase III long-term survival
摘要：

SYHX2011 is a novel albumin-bound paclitaxel formulation designed to simplify drug preparation and reduce skin rash by replacing most non-particulate human serum albumin with mannitol and sucrose. This exploratory analysis evaluated updated survival outcomes after extended follow-up of a multicenter, randomized, doubleblind, phase III trial comparing SYHX2011 with approved albumin-bound paclitaxel (PAB; Keaili (R)) in patients with unresectable locally advanced or metastatic breast cancer. Overall, 459 patients were randomized 1:1 to receive SYHX2011 or PAB. At the December 29, 2025 data cutoff, median follow-up was 25.2 and 25.0 months, respectively. Median progression-free survival (PFS) was 7.6 months with SYHX2011 and 5.6 months with PAB (p=0.028; hazard ratio [HR]=0.79, 95% confidence interval [CI]: 0.63-1.01). Median overall survival (OS) was not reached with SYHX2011 and was 24.3 months with PAB (p=0.11; HR=0.84, 95% CI: 0.64-1.11). Descriptive trends toward longer PFS and OS with SYHX2011 were observed across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Although OS data remain immature and subgroup findings require cautious interpretation, the updated results support continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option for advanced breast cancer.
推荐引用方式
GB/T 7714：

Tang Tiantian,Wang Jingxuan,Sun Tao, et al. Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial [J].BIOMOLECULES AND BIOMEDICINE,2026.
APA：

Tang Tiantian,Wang Jingxuan,Sun Tao,Zhang Lina,&Zhang Qingyuan.(2026).Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial .BIOMOLECULES AND BIOMEDICINE.
MLA：

Tang Tiantian, et al. "Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial" .BIOMOLECULES AND BIOMEDICINE(2026).
入库时间：

8/13/2026 9:49:15 PM
更新时间：

8/13/2026 9:49:15 PM

浏览次数：1  下载次数：0

分享到：

浏览次数：1

下载次数：0

打印次数：0